Sabizabulin

N/A

Report date: 2022/06/14 14:56:59
NME

Base Information

Drug NameSabizabulin
Drug Alias NameVERU-111BisindoleAPP-111
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metastatic breast cancerHormone-Resistant Prostate Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesMexico +[6] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesVeru HealthcareThe Ohio State University
China Registration ClassN/A

Develop Information

Active CompaniesVeru HealthcareVeru Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultProstatic Neoplasms
Inactive IndicationsMetastatic breast cancerHormone-Resistant Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant +[4] 

Other Information

ATC CodeN/A
Related LinksN/A